Please assess the completion status of the following clinical trial:

Trial Title: Lamivudine and Adefovir Dipivoxil Fixed Dose Combination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy as determined by a responsible physician.~* Male 18 and 55 years of age.~* Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods.~* Body weight \>50 kg (110 lbs) and body mass index (BMI) between 19.0 and 25.0.~* Capable of giving written informed consent.~* QT interval corrected according to Bazzett's formula (QTcB) or QT interval corrected according to Fridericia's formula (QTcF) \<450 msec; or QTc \<480 msec in subjects with Bundle Branch Block.~* AST, ALT, alkaline phosphatase and bilirubin \<=1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).~Exclusion Criteria:~* Any clinically relevant abnormality identified on the screening history, physical or laboratory examination, or any other medical condition or circumstance making the subject unsuitable for participation in the study.~* Treatment with any prescription or non-prescription drugs (including vitamins, herbal and dietary supplements, as well as grapefruit-containing products) within 7 days or five half-lives prior to first dose of study medication and until the end of the study. Excluded from this list is acetaminophen at doses of \<=2 grams/day.~* Treatment with an investigational drug within 30 days or five half-lives (whichever is longer) preceding Day 1 of treatment period 1.~* Exposure to more than four new chemical entities within 12 months prior to the first dosing day.~* History of regular alcohol consumption exceeding 7 drinks/week for women or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening.~* Positive urine drug screen (UDS) or breath alcohol test at screening. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.~* Positive for hepatitis B, hepatitis C or HIV.~* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).~* Electrocardiogram findings as follows (a single repeat is allowed for eligibility determination):~Parameter Males Heart rate \<45 and \>100 beats per minute PR Interval \<120 and \>220 msec QRS duration \<70 and \>120 msec QTc interval (Bazett) \>450 msec~* Evidence of previous myocardial infarction (does not include ST segment changes associated with repolarization).~* Any conduction abnormality (including but not specific to left or right complete bundle branch block, atrio-ventricular block \[second degree or higher\], Wolf Parkinson White syndrome).~* Sinus pauses \>3 seconds.~* Any significant arrhythmia which, in the opinion of the principal Investigator and GlaxoSmithKline medical monitor, will interfere with the safety for the individual subject.~* Non-sustained or sustained ventricular tachycardia (\>=3 consecutive ventricular ectopic beats).~  * Documented history of low blood pressure (BP; average systolic BP\<=90 mmHg and/or diastolic BP \<=45 mm Hg) or blood pressure below these values at time of screening.~ * Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.~ * History of asthma or chronic obstructive pulmonary disease.~ * History of sensitivity to heparin, heparin- induced thrombocytopenia, or sensitivity to any of the study medications or components thereof.~ * History of anaphylaxis or anaphylactic reactions or severe allergic responses to drugs.~ * History of angioedema.~ * Unwillingness or inability to follow the procedures outlined in the protocol or inability to provide written informed consent.~ * Subject is mentally or legally incapacitated

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Lamivudine and Adefovir dipivoxil (Type: ACTIVE_COMPARATOR): One 100mg Lamivudine tablet and One 10mg Adefovir dipivoxil tablet
- Fixed dose combination (Type: EXPERIMENTAL): One capsule (100mg lamivudine and 10mg adefovir dipivoxil)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete